Preoperative Administration of Heparin as Thromboprophylaxis in Major Thoracic Surgery

October 21, 2016 updated by: Yi-Dan Lin, West China Hospital

Safety and Efficacy of Preoperative Administration of Heparin as Thromboprophylaxis in Major Thoracic Surgery

Thromboembolism is an important perioperative complication in major thoracic surgery, even though current guidelines have recommended postoperative administration of heparin or LMWH for thromboprophylaxis for those high-risk patients, there are still many cases of thromboembolism. Therefore, as the guideline itself writes, the investigators believe the rational of dose and timing of heparin in thoracic surgery are still not well established. Therefore, the investigators aimed to conduct this randomized controlled study to explore the safety and efficacy of preoperative Administration of Heparin as Thromboprophylaxis in Major Thoracic Surgery.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Anticipated)

2000

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Sichuan
      • Chengdu, Sichuan, China, 610041
        • Recruiting
        • Department of thoracic surgery, west china hospital, sichuan university
        • Contact:
        • Principal Investigator:
          • Yi-Dan Lin, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • 18-75 years old without any preoperative VTEs;
  • patients undergoing major thoracic surgery (including lobectomy, esophagectomy, and thymectomy).

Exclusion Criteria:

  • patients with coagulation disorders: preoperative international normalized ratio (INR) > 1.5, or blood platelet count < 50x10^9/L;
  • patients receiving any therapeutic anticoagulation preoperatively;
  • patients with severe renal or liver dysfunction.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: case group
start heparin sodium (5000IU, BID) upon admission, and continue until discharge
Active Comparator: control group
start heparin sodium (5000 IU,BID) from postoperative day 1, and continue until discharge

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
intraoperative bleeding volume (ml)
Time Frame: the bleeding volume (ml) during operation in the operation room for all patients
During the operation, the blood loss of each patient was collected and measured, and recorded by the investigators.
the bleeding volume (ml) during operation in the operation room for all patients
chest tube drainage volume (ml)
Time Frame: from postoperative day 1 to chest tube remove(usually on postoperative day 3 for lobectomy or thymectomy,on postoperative day 7 for esophagectomy )
from postoperative day 1 to chest tube remove(usually on postoperative day 3 for lobectomy or thymectomy,on postoperative day 7 for esophagectomy )
thromboembolism occurence rate (%)
Time Frame: within 30 days after surgery
within 30 days after surgery
APTT (s)
Time Frame: on postoperative day 1 for both group
on postoperative day 1 for both group
PT(s)
Time Frame: on postoperative day 1 for both group
on postoperative day 1 for both group
INR
Time Frame: on postoperative day 1 for both group
on postoperative day 1 for both group
blood platlet count(/L)
Time Frame: on postoperative day 1 for both group
on postoperative day 1 for both group
chest tube drainage duration (days)
Time Frame: from postoperative day 1 to chest tube remove(usually on postoperative day 3 for lobectomy or thymectomy,on postoperative day 7 for esophagectomy )
from postoperative day 1 to chest tube remove(usually on postoperative day 3 for lobectomy or thymectomy,on postoperative day 7 for esophagectomy )

Secondary Outcome Measures

Outcome Measure
Time Frame
PT(s)
Time Frame: rightly upon hospital admission day
rightly upon hospital admission day
APTT(s)
Time Frame: rightly upon hospital admission day
rightly upon hospital admission day
INR
Time Frame: rightly upon hospital admission day
rightly upon hospital admission day
blood platlet count(/L)
Time Frame: rightly upon hospital admission day
rightly upon hospital admission day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2016

Primary Completion (Anticipated)

June 1, 2018

Study Completion (Anticipated)

June 1, 2018

Study Registration Dates

First Submitted

October 17, 2016

First Submitted That Met QC Criteria

October 20, 2016

First Posted (Estimate)

October 21, 2016

Study Record Updates

Last Update Posted (Estimate)

October 24, 2016

Last Update Submitted That Met QC Criteria

October 21, 2016

Last Verified

October 1, 2016

More Information

Terms related to this study

Other Study ID Numbers

  • WCH-20160601

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.